ChiRhoClin, Inc.
10
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
30.0%
3 terminated/withdrawn out of 10 trials
62.5%
-24.0% vs industry average
30%
3 trials in Phase 3/4
80%
4 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects
Role: collaborator
Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency
Role: collaborator
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Role: collaborator
Secretin for Acute Pancreatitis
Role: lead
Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis
Role: collaborator
Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)
Role: collaborator
Secretin Infusion for Pain Due to Chronic Pancreatitis
Role: lead
Endoscopic Ultrasound Compared With Pancreatic Function Testing for Diagnosis of Chronic Pancreatitis
Role: collaborator
Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma
Role: collaborator
A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers
Role: lead
All 10 trials loaded